Grifols dosed the first patient in its global SWIFT-SC Phase 3 clinical trial. This study evaluates a new subcutaneous formulation of Alpha1-Proteinase Inhibitor for alpha-1 antitrypsin (AAT) deficiency.
The new formulation has a concentration approximately three times higher than the standard intravenous version. This higher concentration potentially allows for self-administration and greater patient flexibility.
This trial is the first Phase 3 study to assess a subcutaneous augmentation therapy for AAT deficiency. It follows a successful Phase 1/2 study.
The project complements the company's SPARTA study, which expects to report top-line results by the end of the year. Grifols aims to provide more convenient treatment options for patients with lung and liver disease.